Uniqure B.V. buy melinda
Start price
27.06.17
/
50%
€5.41
Target price
18.07.17
€6.13
Performance (%)
7.52%
End price
18.07.17
€5.82
Summary
This prediction ended on 18.07.17 with a price of €5.82. With a performance of 7.52%, the BUY prediction by melinda for Uniqure B.V. closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Uniqure B.V. | -0.329% | -0.329% | 43.844% | -7.582% |
| iShares Core DAX® | -1.875% | 2.861% | 18.863% | 63.672% |
| iShares Nasdaq 100 | -2.177% | 0.048% | 3.956% | 109.562% |
| iShares Nikkei 225® | -0.867% | 6.987% | 21.062% | 54.912% |
| iShares S&P 500 | -1.253% | 1.248% | 2.246% | 69.801% |
According to melinda what are the pros and cons of Uniqure B.V. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Uniqure B.V. diskutieren
Gesundheit | Biotechnologie | Niederlande
Aktualisiert Phase 1/2 nach dem Kongress der Internationalen Gesellschaft für Thrombose und Hämostase (ISTH) 2017, die 11. Juli 2017. Phase - 2b - Studie zu Q3 2017 beginnen.
Stopped prediction by melinda for Uniqure B.V.
Uniqure B.V.
Start price
Target price
Perf. (%)
€19.00
27.12.21
27.12.21
-
27.12.22
27.12.22
8.55%
28.12.22
28.12.22
Could be worthwhile Investment >10% per year
Uniqure B.V.
Start price
Target price
Perf. (%)
€32.45
29.08.20
29.08.20
€40.00
04.11.21
04.11.21
-7.18%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Uniqure B.V.
Start price
Target price
Perf. (%)
€38.10
30.08.18
30.08.18
€40.59
25.02.19
25.02.19
31.53%
25.02.19
25.02.19
Could be worthwhile Investment >10% per year